The Clinical Trials Transformation Initiative (CTTI), a growing, broad-based coalition of organizations dedicated to modernizing the way clinical trials are conducted in the United States, has named a 12-member Executive Board that will oversee its activities.
Founded by the U.S. Food and Drug Administration (FDA) and Duke University as a public-private partnership, CTTI seeks to improve the quality and efficiency of clinical trials. CTTI was formed in the wake of growing frustration among patients, consumers, the academic community and industry over the difficulty of conducting high-quality clinical trials in a timely manner that could produce information physicians need to define optimal treatments for their patients.
This board comprises leading figures in government, academia, industry (pharmaceutical, biotechnology, device and contract research) and patient advocacy.
C3 Board Chair Nancy Roach has been named a member of the CTTI Executive Board as the only representative of the patient advocacy community.